The Janssen Pharmaceutical Companies of Johnson & Johnson has reported final data from the Phase II GRIFFIN clinical trial of Darzalex (daratumumab) plus lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone (Darzalex-RVd) in recently diagnosed patients with multiple myeloma.

The randomised trial analysed the investigational usage of the Darzalex-RVd regimen in over 200 adult subjects aged 18 to 70 years with multiple myeloma, who are eligible for post-autologous stem cell transplant (ASCT).

It evaluated the Darzalex-RVd regimen which was followed by maintenance therapy comprising Darzalex-lenalidomide (R) versus RVd followed by maintenance therapy with R alone.

According to the final assessment data, Darzalex-RVd offered a minimal residual disease (MRD) negativity rate of 64% compared to 30% in the RVd arm following two years of maintenance therapy.

In the trial, 44% of the subjects in the Darzalex-RVd arm attained sustained MRD negativity that lasted 12 months or more versus 14% in the RVd arm.

Additionally, Darzalex-RVd treatment offered greater stringent complete response (sCR) rates at all time points in the trial, with top rates seen after two years of maintenance therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

In the Darzalex-RVd arm, CR or better rate was found to be 83% compared to 60% in the RVd arm.

A 55% decline in the disease progression or mortality risk was seen in subjects in the Darzalex-RVd arm following 49.6 months of median follow-up.

No new safety concerns were reported following extended follow-up in the trial.

Darzalex is a CD38-directed antibody.

Janssen Scientific Affairs Hematology Medical Affairs US vice-president Imran Khan said: “The Phase II GRIFFIN study showed important results with the investigational Darzalex quadruplet regimen in the treatment of newly diagnosed, transplant-eligible multiple myeloma.

“The evaluation of this treatment regimen will continue as part of the registrational, Phase III PERSEUS study.”